These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 33856568

  • 1. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
    Sun Y, Qin L, Li J, Su J, Song R, Zhang X, Guan J, Mao S.
    AAPS J; 2021 Apr 15; 23(3):55. PubMed ID: 33856568
    [Abstract] [Full Text] [Related]

  • 2. Elucidation of lactose fine size and drug shape on rheological properties and aerodynamic behavior of dry powders for inhalation.
    Sun Y, Yu D, Li J, Zhao J, Feng Y, Zhang X, Mao S.
    Eur J Pharm Biopharm; 2022 Oct 15; 179():47-57. PubMed ID: 36029939
    [Abstract] [Full Text] [Related]

  • 3. Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
    He X, Li J, Wen X, Ma S, An Y, Zhang X, Guan J, Mao S.
    Int J Pharm; 2024 Oct 25; 664():124609. PubMed ID: 39163928
    [Abstract] [Full Text] [Related]

  • 4. Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.
    Hertel M, Schwarz E, Kobler M, Hauptstein S, Steckel H, Scherließ R.
    Int J Pharm; 2018 Jan 15; 535(1-2):59-67. PubMed ID: 29100914
    [Abstract] [Full Text] [Related]

  • 5. Exploring the influence of drug content on DPI powder properties and potential prediction of pulmonary drug deposition.
    Sun Y, Qin L, Liu C, Su J, Zhang X, Yu D, Guo C, Lu H, Li L, Xiong W, Mao S.
    Int J Pharm; 2020 Feb 15; 575():119000. PubMed ID: 31893544
    [Abstract] [Full Text] [Related]

  • 6. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W, Ticehurst MD, Murphy J, Nokhodchi A.
    J Pharm Sci; 2011 Jul 15; 100(7):2665-84. PubMed ID: 21268026
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Exploring the potential influence of drug charge on downstream deposition behaviour of DPI powders.
    Sun Y, Cui Z, Sun Y, Qin L, Zhang X, Liu Q, Shen X, Yu D, Mao S.
    Int J Pharm; 2020 Oct 15; 588():119798. PubMed ID: 32828976
    [Abstract] [Full Text] [Related]

  • 9. Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance.
    Faulhammer E, Wahl V, Zellnitz S, Khinast JG, Paudel A.
    Int J Pharm; 2015 Aug 01; 491(1-2):231-42. PubMed ID: 26136200
    [Abstract] [Full Text] [Related]

  • 10. Elucidation of the effect of added fines on the performance of dry powder inhalation formulations.
    Stankovic-Brandl M, Radivojev S, Sailer P, Penz FK, Paudel A.
    Int J Pharm; 2022 Dec 15; 629():122359. PubMed ID: 36332830
    [Abstract] [Full Text] [Related]

  • 11. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW.
    Int J Pharm; 2006 Mar 09; 310(1-2):81-9. PubMed ID: 16442246
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P, Du J, Smyth HDC.
    J Pharm Sci; 2017 Jan 09; 106(1):366-376. PubMed ID: 27939234
    [Abstract] [Full Text] [Related]

  • 13. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ, Jain RR, Soni PS, Abdul S, Darshana H, Gaikwad RV, Menon MD.
    J Aerosol Med Pulm Drug Deliv; 2015 Aug 09; 28(4):254-67. PubMed ID: 25517187
    [Abstract] [Full Text] [Related]

  • 14. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.
    Shur J, Harris H, Jones MD, Kaerger JS, Price R.
    Pharm Res; 2008 Jul 09; 25(7):1631-40. PubMed ID: 18239861
    [Abstract] [Full Text] [Related]

  • 15. Effect of carrier particle shape on dry powder inhaler performance.
    Kaialy W, Alhalaweh A, Velaga SP, Nokhodchi A.
    Int J Pharm; 2011 Dec 12; 421(1):12-23. PubMed ID: 21945739
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
    Jones MD, Santo JG, Yakub B, Dennison M, Master H, Buckton G.
    Int J Pharm; 2010 May 31; 391(1-2):137-47. PubMed ID: 20211715
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO, Molokhia AM, Elsayed MM.
    Eur J Pharm Biopharm; 2015 Oct 31; 96():291-303. PubMed ID: 26275831
    [Abstract] [Full Text] [Related]

  • 20. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices.
    Ooi J, Gill C, Young PM, Traini D.
    Curr Drug Deliv; 2015 Oct 31; 12(1):40-6. PubMed ID: 25146438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.